Fisetin Testing & Transparency Report 2026
An audit of what current fisetin and senolytic product sources actually disclose about testing, Certificates of Analysis and manufacturing quality.
Snapshot
10/21
Entries with explicit testing or equivalent retailer verification in the reviewed source.
8/21
Entries where a COA was explicitly captured as visible.
6/10
Median Transparency Score across the Phase 3 sample.
Transparency table
| Rank | Product | Testing | COA | GMP | Transparency | Evidence Match |
|---|---|---|---|---|---|---|
| 1 | Double Wood Fisetin Supplement | Yes | Yes | Yes | 10/10 | 9/10 |
| 2 | ProHealth Longevity Pure Fisetin | Yes | Yes | Yes | 10/10 | 9/10 |
| 3 | Toniiq Fisetin 500 | Yes | Yes | Yes | 10/10 | 8/10 |
| 4 | ProHealth Longevity Rapid Reset Multi-Senolytic | Yes | Yes | Yes | 10/10 | 7/10 |
| 5 | Toniiq Senolytic+ 4000 | Yes | Yes | Yes | 10/10 | 7/10 |
| 6 | Toniiq Qova | Yes | Yes | Yes | 10/10 | 7/10 |
| 7 | California Gold Nutrition Fisetin with Novusetin | iTested / retailer verification | Not captured | Third-party audited cGMP facility | 8/10 | 9/10 |
| 8 | California Gold Nutrition Fisetin with BeFisetin | iTested verified | Not captured | Third-party audited cGMP facility | 8/10 | 9/10 |
| 9 | ProHealth Longevity Fisetin Pro Longevity Plus | Not separately captured | Yes | Not captured | 7/10 | 7/10 |
| 10 | Renue By Science LIPO Fisetin | Yes | Yes | Not captured | 7/10 | 6/10 |
| 11 | DoNotAge.org Pure Fisetin | Brand site says third-party tested | Not captured | Not captured | 6/10 | 8/10 |
| 12 | Doctor's Best Fisetin with Novusetin | Not captured | Not captured | Not captured | 5/10 | 8/10 |
| 13 | Vitacost Fisetin Flavonoid | Not captured | Not captured | Not captured | 5/10 | 7/10 |
| 14 | Life Extension Bio-Fisetin | Not captured | Not captured | Not captured | 5/10 | 6/10 |
| 15 | Swanson Vitamins Fisetin Novusetin | Not captured | Not captured | Not captured | 4/10 | 7/10 |
| 16 | Humanx Fisetin | Not captured | Not captured | Not captured | 4/10 | 6/10 |
| 17 | Nature's Fusions Nutri Fisetin Extra Strength | Not captured | Not captured | Not captured | 4/10 | 6/10 |
| 18 | Neurogan Health Fisetin | Not captured | Not captured | Not captured | 4/10 | 6/10 |
| 19 | Nutricost Fisetin | Not captured | Not captured | Not captured | 4/10 | 6/10 |
| 20 | Dr. Mercola Fisetin and Spermidine | Not captured | Not captured | Not captured | 2/10 | 2/10 |
| 21 | Elysium Senolytic Complex | Not captured | Not captured | Not captured | 2/10 | 2/10 |
What this report does not prove
A visible COA or third-party-testing statement makes a product easier to audit. It does not prove that the supplement produces a superior health outcome. Likewise, a missing disclosure in our source does not prove the company never tests its product. The report measures disclosed transparency at the time of review.
Why testing transparency matters
A product can make strong quality claims while revealing very little about how those claims are verified. Testing transparency makes the quality story easier to audit.
What counts as stronger disclosure
Visible batch COAs, contaminant testing, potency testing, and clear laboratory or certification information provide more useful evidence than a generic “lab tested” badge.
What a COA can and cannot prove
A COA can help confirm identity, potency, and certain contaminants for a batch, but it does not prove clinical effectiveness.
Third-party testing versus certification
Third-party testing can mean many things. Formal certification programs usually impose clearer standards than an unexplained claim that testing occurred.
Why some products score lower
A lower transparency score can reflect missing public information rather than confirmed poor quality. The score measures auditability, not hidden facts.
How current the document should be
A testing document is more useful when the batch, date, and product match the item being sold now.
How this affects rankings
Testing transparency should influence commercial recommendations because buyers are paying for a finished product, not merely a molecule name.
Update policy
Testing pages and COAs change. Scores should be revised when brands publish new documents or remove old ones.
Update trigger 1
For Fisetin Testing & Transparency Report 2026, the conclusion should remain open to revision. New human studies, formula changes, updated COAs, price changes, and newly disclosed testing can all alter the commercial recommendation. The useful goal is not to create a permanent winner, but to make the comparison transparent enough that readers can see why the conclusion was reached and what evidence would change it.
Update trigger 2
For Fisetin Testing & Transparency Report 2026, the conclusion should remain open to revision. New human studies, formula changes, updated COAs, price changes, and newly disclosed testing can all alter the commercial recommendation. The useful goal is not to create a permanent winner, but to make the comparison transparent enough that readers can see why the conclusion was reached and what evidence would change it.
Update trigger 3
For Fisetin Testing & Transparency Report 2026, the conclusion should remain open to revision. New human studies, formula changes, updated COAs, price changes, and newly disclosed testing can all alter the commercial recommendation. The useful goal is not to create a permanent winner, but to make the comparison transparent enough that readers can see why the conclusion was reached and what evidence would change it.
Update trigger 4
For Fisetin Testing & Transparency Report 2026, the conclusion should remain open to revision. New human studies, formula changes, updated COAs, price changes, and newly disclosed testing can all alter the commercial recommendation. The useful goal is not to create a permanent winner, but to make the comparison transparent enough that readers can see why the conclusion was reached and what evidence would change it.
Update trigger 5
For Fisetin Testing & Transparency Report 2026, the conclusion should remain open to revision. New human studies, formula changes, updated COAs, price changes, and newly disclosed testing can all alter the commercial recommendation. The useful goal is not to create a permanent winner, but to make the comparison transparent enough that readers can see why the conclusion was reached and what evidence would change it.
Update trigger 6
For Fisetin Testing & Transparency Report 2026, the conclusion should remain open to revision. New human studies, formula changes, updated COAs, price changes, and newly disclosed testing can all alter the commercial recommendation. The useful goal is not to create a permanent winner, but to make the comparison transparent enough that readers can see why the conclusion was reached and what evidence would change it.
Update trigger 7
For Fisetin Testing & Transparency Report 2026, the conclusion should remain open to revision. New human studies, formula changes, updated COAs, price changes, and newly disclosed testing can all alter the commercial recommendation. The useful goal is not to create a permanent winner, but to make the comparison transparent enough that readers can see why the conclusion was reached and what evidence would change it.
Update trigger 8
For Fisetin Testing & Transparency Report 2026, the conclusion should remain open to revision. New human studies, formula changes, updated COAs, price changes, and newly disclosed testing can all alter the commercial recommendation. The useful goal is not to create a permanent winner, but to make the comparison transparent enough that readers can see why the conclusion was reached and what evidence would change it.
Update trigger 9
For Fisetin Testing & Transparency Report 2026, the conclusion should remain open to revision. New human studies, formula changes, updated COAs, price changes, and newly disclosed testing can all alter the commercial recommendation. The useful goal is not to create a permanent winner, but to make the comparison transparent enough that readers can see why the conclusion was reached and what evidence would change it.